Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ANIXBullishIndustry Newsnews

High materiality7/10

Anixa reports Phase 1 success for breast vaccine and ovarian CAR-T

Jun 26, 2026, 9:13 AM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong Phase 1 signals (74% immune responses) and high-profile collaborations can lift sentiment and attract speculative buying. Yet, data are from early trials with no regulatory milestones; historical biotech moves on Phase 1 data are often volatile and can fade without confirmatory reads.

AI summary

What happened, with direct paths to the underlying reporting

Anixa Biosciences disclosed positive Phase 1 data for its alpha-lactalbumin breast cancer vaccine, with all primary endpoints reached and 74% immune responses. It also reported survival observations from its lira-cel ovarian cancer CAR-T in an ongoing Phase 1 trial. The disclosures, made alongside Cleveland Clinic and Moffitt Cancer Center, underscore pipeline momentum and potential downstream validation.

Phase 1 breast cancer vaccine: all primary endpoints met; 74% immune responses.
Lira-cel ovarian cancer CAR-T shows positive survival observations in ongoing Phase 1.
Presentations at NY Academy of Sciences; collaborations with Cleveland Clinic and Moffitt.
Two programs highlighted; progress supported by leading cancer research institutions.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Anixa reports Phase 1 success for breast vaccine and ovarian CAR-T

EXCLUSIVE: Anixa Biosciences' Ovarian Cancer Drug Candidate Shows Longer Survival With No Major Safety Issues